Skip to main content
Top

15-04-2024 | Ascites | Original Article

Longitudinal changes in bone mineral density may be associated with long-term survival in patients with cirrhosis: A proof of concept of study

Authors: Samagra Agarwal, Sanchit Sharma, Indu Grover, Namrata Singh, Syed Ahmed, Anoop Saraya

Published in: Indian Journal of Gastroenterology

Login to get access

Abstract

Introduction

The impact of longitudinal changes in different body components measured via body composition analysis (BCA) on liver-related outcomes in patients with cirrhosis is poorly understood. We evaluated the prognostic relevance of longitudinal changes in body composition over one year in patients with cirrhosis.

Methods

This was a follow-up study of a randomized controlled trial evaluating changes in bone density measured via dual energy X-ray absorptiometry (DEXA) upon vitamin D supplementation. Patients with available anthropometric indices, fat mass (FM), fat-free mass (FFM), bone-density at lumbar spine (LD) and left femur-neck (FD) (assessed by T score) at two time points one year apart were assessed for outcomes. The prognostic relevance of change in parameters such as ΔFM, ΔFFM, ΔLD and ΔFD over one year was assessed and compared with baseline model for end-stage liver disease (MELD) score.

Results

Patients with cirrhosis (n=112) (mean age 41.8±12 years, 58.5% males) were followed up for median duration of 5.7 years interquartile range [IQR 3.5–5.7], with five-year survival rate of 77%. On serial BCA, ΔLD (p=0.029) and ΔFD (p=0.003) emerged as significant predictors of survival, whereas ΔFM (p=0.479), ΔFFM (p=0.245) and ΔBMI (p=0.949) were not. The area under curve of ΔLD and MELD score for predicting survival was 0.636 (0.5–0.773) and 0.664 (0.555–0.773), respectively. ΔFD<0.1 over one year had sensitivity and specificity of 70.4% and 56.5% to predict poor survival. The combination of ΔFD, MELD and ascites predicted five-year survival with an optimism-corrected c-statistic of 0.785.

Conclusion

Among body composition parameters, changes in bone mineral density correlate best with survival and have prognostic relevance similar to that of ascites and MELD score.

Graphical Abstract

Appendix
Available only for authorised users
Literature
1.
go back to reference Figueiredo FAF, De Mello PR, Kondo M. Effect of liver cirrhosis on body composition: evidence of significant depletion even in mild disease. J Gastroenterol Hepatol. 2005;20:209–16.CrossRefPubMed Figueiredo FAF, De Mello PR, Kondo M. Effect of liver cirrhosis on body composition: evidence of significant depletion even in mild disease. J Gastroenterol Hepatol. 2005;20:209–16.CrossRefPubMed
2.
go back to reference Engelmann C, Aehling NF, Schob S, et al. Body fat composition determines outcomes before and after liver transplantation in patients with cirrhosis. Hepatol Commun. 2022;6:2198–209.CrossRefPubMedPubMedCentral Engelmann C, Aehling NF, Schob S, et al. Body fat composition determines outcomes before and after liver transplantation in patients with cirrhosis. Hepatol Commun. 2022;6:2198–209.CrossRefPubMedPubMedCentral
5.
go back to reference Chinnaratha MA, Chaudhary S, Doogue M, et al. Prevalence of hepatic osteodystrophy and vitamin D deficiency in cirrhosis. Intern Med J. 2015;45:1230–5.CrossRefPubMed Chinnaratha MA, Chaudhary S, Doogue M, et al. Prevalence of hepatic osteodystrophy and vitamin D deficiency in cirrhosis. Intern Med J. 2015;45:1230–5.CrossRefPubMed
6.
go back to reference Singh S, Taneja S, Tandon P, et al. High prevalence of hormonal changes and hepatic osteodystrophy in frail patients with cirrhosis—an observational study. J Clin Exp Hepatol. 2022;12:800–7.CrossRefPubMed Singh S, Taneja S, Tandon P, et al. High prevalence of hormonal changes and hepatic osteodystrophy in frail patients with cirrhosis—an observational study. J Clin Exp Hepatol. 2022;12:800–7.CrossRefPubMed
7.
go back to reference Hidalgo DF, Boonpheng B, Sikandar S, Nasr L, Hidalgo J. Chronic liver disease and the risk of osteoporotic fractures: a meta-analysis. Cureus. 2020;12:e10483.PubMedPubMedCentral Hidalgo DF, Boonpheng B, Sikandar S, Nasr L, Hidalgo J. Chronic liver disease and the risk of osteoporotic fractures: a meta-analysis. Cureus. 2020;12:e10483.PubMedPubMedCentral
8.
go back to reference Grover I, Gunjan D, Singh N, et al. Effect of vitamin D supplementation on vitamin D level and bone mineral density in patients with cirrhosis: a randomized clinical trial. Am J Gastroenterol. 2021;116:2098–104.CrossRefPubMed Grover I, Gunjan D, Singh N, et al. Effect of vitamin D supplementation on vitamin D level and bone mineral density in patients with cirrhosis: a randomized clinical trial. Am J Gastroenterol. 2021;116:2098–104.CrossRefPubMed
9.
go back to reference Grover I, Singh N, Gunjan D, et al. Comparison of anthropometry, bioelectrical impedance, and dual-energy X-ray absorptiometry for body composition in cirrhosis. J Clin Exp Hepatol. 2022;12:467–74.CrossRefPubMed Grover I, Singh N, Gunjan D, et al. Comparison of anthropometry, bioelectrical impedance, and dual-energy X-ray absorptiometry for body composition in cirrhosis. J Clin Exp Hepatol. 2022;12:467–74.CrossRefPubMed
10.
go back to reference Angeli P, Bernardi M, Villanueva C, et al. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69:406–60.CrossRef Angeli P, Bernardi M, Villanueva C, et al. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69:406–60.CrossRef
12.
go back to reference D’Amico G, Pasta L, Morabito A, et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther. 2014;39:1180–93.CrossRefPubMed D’Amico G, Pasta L, Morabito A, et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther. 2014;39:1180–93.CrossRefPubMed
13.
go back to reference Merli M, Berzigotti A, Zelber-Sagi S, et al. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol. 2019;70:172–93.CrossRef Merli M, Berzigotti A, Zelber-Sagi S, et al. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol. 2019;70:172–93.CrossRef
14.
go back to reference Song Z, Chen W, Athavale D, et al. Osteopontin takes center stage in chronic liver disease. Hepatol Baltim Md. 2021;73:1594–608.CrossRef Song Z, Chen W, Athavale D, et al. Osteopontin takes center stage in chronic liver disease. Hepatol Baltim Md. 2021;73:1594–608.CrossRef
15.
go back to reference Staiger H, Keuper M, Berti L. Hrabe de Angelis M, Häring HU. Fibroblast growth factor 21-metabolic role in mice and men. Endocr Rev. 2017;38:468–88.CrossRefPubMed Staiger H, Keuper M, Berti L. Hrabe de Angelis M, Häring HU. Fibroblast growth factor 21-metabolic role in mice and men. Endocr Rev. 2017;38:468–88.CrossRefPubMed
16.
17.
Metadata
Title
Longitudinal changes in bone mineral density may be associated with long-term survival in patients with cirrhosis: A proof of concept of study
Authors
Samagra Agarwal
Sanchit Sharma
Indu Grover
Namrata Singh
Syed Ahmed
Anoop Saraya
Publication date
15-04-2024
Publisher
Springer India
Keyword
Ascites
Published in
Indian Journal of Gastroenterology
Print ISSN: 0254-8860
Electronic ISSN: 0975-0711
DOI
https://doi.org/10.1007/s12664-023-01504-y
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.